nrf2 activator rta 408 Search Results


rta 408  (MedChemExpress)
94
MedChemExpress rta 408
Human primers.
Rta 408, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rta 408/product/MedChemExpress
Average 94 stars, based on 1 article reviews
rta 408 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
nrf2 activator rta 408  (Reata Pharmaceuticals)
90
Reata Pharmaceuticals nrf2 activator rta 408
<t>Nrf2-inducers</t> up-regulate the Nrf2 expression in frataxin silenced neurons (shFxn). ( A ) qRT-PCR of mRNA Nrf2 levels in shFxn and Mock after 5 µM (24 h) sulforaphane (SFN) and 30 µM (24 h) dimethyl fumarate (DMF) treatments. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is used for normalization and relative quantification of gene expression was performed according to the 2 −ΔΔ C t method; ( B ) Representative Western blot of DMF- and SFN-treated shFxn neurons; ( C ) Densitometry of Nrf2 protein amounts analyzed by Western Blot. Values represent the mean ± SD of three independent experiments (** p < 0.01 and *** p < 0.001, with respect to Mock; # p < 0.05 and ### p < 0.001, with respect to untreated shFxn).
Nrf2 Activator Rta 408, supplied by Reata Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nrf2 activator rta 408/product/Reata Pharmaceuticals
Average 90 stars, based on 1 article reviews
nrf2 activator rta 408 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
znrf2 hdr plasmid  (Santa Cruz Biotechnology)
N/A
CRISPR Cas9 KO Plasmids consists of ZNRF2 specific 20 nt guide RNA sequences derived from the GeCKO v2 library For CRISPR gene knockout gRNA sequences direct the Cas9 protein to induce a site specific double
   Buy from Supplier
znrf2 double nickase plasmid  (Santa Cruz Biotechnology)
N/A
CRISPR Cas9 KO Plasmids consists of ZNRF2 specific 20 nt guide RNA sequences derived from the GeCKO v2 library For CRISPR gene knockout gRNA sequences direct the Cas9 protein to induce a site specific double
   Buy from Supplier
znrf2 crispr activation plasmid  (Santa Cruz Biotechnology)
N/A
CRISPR Cas9 KO Plasmids consists of ZNRF2 specific 20 nt guide RNA sequences derived from the GeCKO v2 library For CRISPR gene knockout gRNA sequences direct the Cas9 protein to induce a site specific double
   Buy from Supplier
nrf2 colorimetric cell-based elisa kit  (Boster Bio)
N/A
The Nrf2 Cell-Based ELISA Kit is a convenient, lysate-free, high throughput and sensitive assay kit that can monitor Nrf2 protein expression profile in cells. The kit can be used for measuring the relative amounts of
   Buy from Supplier
nrf2 protein  (Biosynth Carbosynth)
N/A
Recombinant Human NRF2 protein (His tag)
   Buy from Supplier
znrf2 crispr cas9 ko plasmid  (Santa Cruz Biotechnology)
N/A
CRISPR Cas9 KO Plasmids consists of ZNRF2 specific 20 nt guide RNA sequences derived from the GeCKO v2 library For CRISPR gene knockout gRNA sequences direct the Cas9 protein to induce a site specific double
   Buy from Supplier
znrf2 lentiviral activation particles  (Santa Cruz Biotechnology)
N/A
CRISPR Cas9 KO Plasmids consists of ZNRF2 specific 20 nt guide RNA sequences derived from the GeCKO v2 library For CRISPR gene knockout gRNA sequences direct the Cas9 protein to induce a site specific double
   Buy from Supplier

Image Search Results


Human primers.

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Nrf2 Activation Protects Against Organic Dust and Hydrogen Sulfide Exposure Induced Epithelial Barrier Loss and K. pneumoniae Invasion

doi: 10.3389/fcimb.2022.848773

Figure Lengend Snippet: Human primers.

Article Snippet: 4000) were procured from Sigma-Aldrich whereas RTA-408 (NRF2 activator) was obtained from MedChemExpress USA.

Techniques:

RTA-408 (Nrf2 activator) improved the cell morphology. Phase contrast microscopic images (20X) were captured after the completion of the exposure protocol for 5 days with or without RTA-408 (20ng pre-exposure for 2 hours) treatment followed by exposure to media (control) or ODE (0.5%) or H 2 S (10ppm) or ODE+H 2 S. Repeated exposure to ODE+H 2 S co-exposure caused the increase in the size of the cells (A–C) as compared to controls. Whereas no significant increase in cell size was seen for those treated with ODE or H 2 S alone as compared to controls. Also, nuclear vacuolization was more prominent in ODE+H 2 S co-exposure groups. Pre-exposure to RTA-408 improved the cell size and lowered the nuclear vacuolization in ODE+H 2 S co-exposure group as compared to those without RTA-408 treatment Data (mean ± SEM) analyzed with two-way ANOVA followed by Tukey’s post hoc test is shown (n=4-6/group) and p ≤ 0.05 was considered significant (* compared to basal control, # between basal and RTA-408).

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Nrf2 Activation Protects Against Organic Dust and Hydrogen Sulfide Exposure Induced Epithelial Barrier Loss and K. pneumoniae Invasion

doi: 10.3389/fcimb.2022.848773

Figure Lengend Snippet: RTA-408 (Nrf2 activator) improved the cell morphology. Phase contrast microscopic images (20X) were captured after the completion of the exposure protocol for 5 days with or without RTA-408 (20ng pre-exposure for 2 hours) treatment followed by exposure to media (control) or ODE (0.5%) or H 2 S (10ppm) or ODE+H 2 S. Repeated exposure to ODE+H 2 S co-exposure caused the increase in the size of the cells (A–C) as compared to controls. Whereas no significant increase in cell size was seen for those treated with ODE or H 2 S alone as compared to controls. Also, nuclear vacuolization was more prominent in ODE+H 2 S co-exposure groups. Pre-exposure to RTA-408 improved the cell size and lowered the nuclear vacuolization in ODE+H 2 S co-exposure group as compared to those without RTA-408 treatment Data (mean ± SEM) analyzed with two-way ANOVA followed by Tukey’s post hoc test is shown (n=4-6/group) and p ≤ 0.05 was considered significant (* compared to basal control, # between basal and RTA-408).

Article Snippet: 4000) were procured from Sigma-Aldrich whereas RTA-408 (NRF2 activator) was obtained from MedChemExpress USA.

Techniques: Control

Repeated exposure to ODE and H 2 S decreased the Nrf2 expression. Immunofluorescence microscopy (40X) (A) , western blotting (B-B’) and RT-qPCR (C, D) were performed to quantify the expression of Nrf2 with repeated exposure to ODE and H 2 S in NHBE (A–C) and PCLS (D) . Immunofluorescence microscopy and RT-qPCR showed decreased Nrf2 (Red) expression (A, C) . Mean intensity of NRF2 staining (per 5-8 fields) was calculated to quantify the expression (A’) . Densitometry values (n=4/group) normalized over housekeeping proteins (β-actin) and NRF2 band intensities (relative to control) are shown (b-b’). RTA-408 pre-treatment increased the expression of Nrf2 in H 2 S and ODE+H 2 S group as compared to respective basal group (B-B’) . Also, RTA-408 pre-treatment in NHBE (C) and PCLS (D) showed increased folds of nrf2 transcript as compared to the respective basal groups. Data (mean ± SEM) analyzed with two-way ANOVA followed by Tukey’s post hoc test is shown and p ≤ 0.05 was considered significant (* compared to basal control, # between basal and RTA-408).

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Nrf2 Activation Protects Against Organic Dust and Hydrogen Sulfide Exposure Induced Epithelial Barrier Loss and K. pneumoniae Invasion

doi: 10.3389/fcimb.2022.848773

Figure Lengend Snippet: Repeated exposure to ODE and H 2 S decreased the Nrf2 expression. Immunofluorescence microscopy (40X) (A) , western blotting (B-B’) and RT-qPCR (C, D) were performed to quantify the expression of Nrf2 with repeated exposure to ODE and H 2 S in NHBE (A–C) and PCLS (D) . Immunofluorescence microscopy and RT-qPCR showed decreased Nrf2 (Red) expression (A, C) . Mean intensity of NRF2 staining (per 5-8 fields) was calculated to quantify the expression (A’) . Densitometry values (n=4/group) normalized over housekeeping proteins (β-actin) and NRF2 band intensities (relative to control) are shown (b-b’). RTA-408 pre-treatment increased the expression of Nrf2 in H 2 S and ODE+H 2 S group as compared to respective basal group (B-B’) . Also, RTA-408 pre-treatment in NHBE (C) and PCLS (D) showed increased folds of nrf2 transcript as compared to the respective basal groups. Data (mean ± SEM) analyzed with two-way ANOVA followed by Tukey’s post hoc test is shown and p ≤ 0.05 was considered significant (* compared to basal control, # between basal and RTA-408).

Article Snippet: 4000) were procured from Sigma-Aldrich whereas RTA-408 (NRF2 activator) was obtained from MedChemExpress USA.

Techniques: Expressing, Immunofluorescence, Microscopy, Western Blot, Quantitative RT-PCR, Staining, Control

RTA-408 increased the expression of downstream genes of NRF2 antioxidant pathway. Nrf2 antioxidant downstream genes, nqo1 (A-A’) , hox1 (B-B’) , gclm (C-C’) and gclc (D-D’) were quantified using Rt-qPCR in both NHBE cells (A–D) and PCLS (A’-D’) after the repeated exposure to ODE or H 2 S or ODE+H 2 S with and without pre-exposure to RTA-408. Nrf2 downstream gene expression quantified by RT-qPCR were normalized over media exposed cells (basal control). Repeated exposure to ODE, H 2 S and ODE+ H 2 S decreased the gene expression of nqo1 (A-A’), hox1 (B-B’) as compared to basal control. Pre-treatment with RTA-408 significantly increased the mRNA transcript of nqo1 (A-A’) , hox1 (B-B’) , gclm (C-C’) and gclc (D-D’) after the repeated exposure to ODE or H 2 S or ODE+H 2 S. Data (mean ± SEM) analyzed with two-way ANOVA followed by Tukey’s post hoc test is shown and p ≤ 0.05 was considered significant (* compared to basal control, # between basal and RTA-408).

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Nrf2 Activation Protects Against Organic Dust and Hydrogen Sulfide Exposure Induced Epithelial Barrier Loss and K. pneumoniae Invasion

doi: 10.3389/fcimb.2022.848773

Figure Lengend Snippet: RTA-408 increased the expression of downstream genes of NRF2 antioxidant pathway. Nrf2 antioxidant downstream genes, nqo1 (A-A’) , hox1 (B-B’) , gclm (C-C’) and gclc (D-D’) were quantified using Rt-qPCR in both NHBE cells (A–D) and PCLS (A’-D’) after the repeated exposure to ODE or H 2 S or ODE+H 2 S with and without pre-exposure to RTA-408. Nrf2 downstream gene expression quantified by RT-qPCR were normalized over media exposed cells (basal control). Repeated exposure to ODE, H 2 S and ODE+ H 2 S decreased the gene expression of nqo1 (A-A’), hox1 (B-B’) as compared to basal control. Pre-treatment with RTA-408 significantly increased the mRNA transcript of nqo1 (A-A’) , hox1 (B-B’) , gclm (C-C’) and gclc (D-D’) after the repeated exposure to ODE or H 2 S or ODE+H 2 S. Data (mean ± SEM) analyzed with two-way ANOVA followed by Tukey’s post hoc test is shown and p ≤ 0.05 was considered significant (* compared to basal control, # between basal and RTA-408).

Article Snippet: 4000) were procured from Sigma-Aldrich whereas RTA-408 (NRF2 activator) was obtained from MedChemExpress USA.

Techniques: Expressing, Quantitative RT-PCR, Control

Nrf2-inducers up-regulate the Nrf2 expression in frataxin silenced neurons (shFxn). ( A ) qRT-PCR of mRNA Nrf2 levels in shFxn and Mock after 5 µM (24 h) sulforaphane (SFN) and 30 µM (24 h) dimethyl fumarate (DMF) treatments. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is used for normalization and relative quantification of gene expression was performed according to the 2 −ΔΔ C t method; ( B ) Representative Western blot of DMF- and SFN-treated shFxn neurons; ( C ) Densitometry of Nrf2 protein amounts analyzed by Western Blot. Values represent the mean ± SD of three independent experiments (** p < 0.01 and *** p < 0.001, with respect to Mock; # p < 0.05 and ### p < 0.001, with respect to untreated shFxn).

Journal: International Journal of Molecular Sciences

Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

doi: 10.3390/ijms18102173

Figure Lengend Snippet: Nrf2-inducers up-regulate the Nrf2 expression in frataxin silenced neurons (shFxn). ( A ) qRT-PCR of mRNA Nrf2 levels in shFxn and Mock after 5 µM (24 h) sulforaphane (SFN) and 30 µM (24 h) dimethyl fumarate (DMF) treatments. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is used for normalization and relative quantification of gene expression was performed according to the 2 −ΔΔ C t method; ( B ) Representative Western blot of DMF- and SFN-treated shFxn neurons; ( C ) Densitometry of Nrf2 protein amounts analyzed by Western Blot. Values represent the mean ± SD of three independent experiments (** p < 0.01 and *** p < 0.001, with respect to Mock; # p < 0.05 and ### p < 0.001, with respect to untreated shFxn).

Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

Techniques: Expressing, Quantitative RT-PCR, Quantitative Proteomics, Gene Expression, Western Blot

Nrf2 inducers activate the phase II response in shFxn. ( A ) Representative Western blot of downstream Nrf2 target proteins. An amount of 40 µg Mock, shFxn 5 µM (24 h) SFN and 30 µM (24 h) DMF treatments were applied onto 4–12% Bis–Tris SDS-polyacrylamide gel electrophoresis and probed with anti-NQO-1 (1:1000), MnSOD (1:5000) and Cu/ZnSOD (1:5000) antibodies; ( B ) Densitometry of blots, normalized to GAPDH. Values represent the mean ± SD of three independent experiments (* p < 0.05, with respect to Mock; # p < 0.05, with respect to untreated shFxn).

Journal: International Journal of Molecular Sciences

Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

doi: 10.3390/ijms18102173

Figure Lengend Snippet: Nrf2 inducers activate the phase II response in shFxn. ( A ) Representative Western blot of downstream Nrf2 target proteins. An amount of 40 µg Mock, shFxn 5 µM (24 h) SFN and 30 µM (24 h) DMF treatments were applied onto 4–12% Bis–Tris SDS-polyacrylamide gel electrophoresis and probed with anti-NQO-1 (1:1000), MnSOD (1:5000) and Cu/ZnSOD (1:5000) antibodies; ( B ) Densitometry of blots, normalized to GAPDH. Values represent the mean ± SD of three independent experiments (* p < 0.05, with respect to Mock; # p < 0.05, with respect to untreated shFxn).

Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

Techniques: Western Blot, Polyacrylamide Gel Electrophoresis

HPLC analysis of GSSG ( A ) and GSH ( B ) in shFxn after treatments with 5 µM (24 h) SFN and 30 µM (24 h) DMF. Nrf2 inducers cause repletion of the oxidized (GSSG)/reduced (GSH) glutathione ratio ( C ). * p < 0.05, *** p < 0.001, with respect to Mock.

Journal: International Journal of Molecular Sciences

Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

doi: 10.3390/ijms18102173

Figure Lengend Snippet: HPLC analysis of GSSG ( A ) and GSH ( B ) in shFxn after treatments with 5 µM (24 h) SFN and 30 µM (24 h) DMF. Nrf2 inducers cause repletion of the oxidized (GSSG)/reduced (GSH) glutathione ratio ( C ). * p < 0.05, *** p < 0.001, with respect to Mock.

Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

Techniques:

Nrf2-inducers trigger axonal re-growth in the shFxn. ( A ) Bright field photographs of untreated shFxn, 5 µM (24 h) SFN and 30 µM (24 h) DMF treated cells. A re-organization of the neurites network is evident; ( B ) The number of neurites has been measured by ImageJ software and normalized for number of cells (*** p <0.001; bar = 100 μm).

Journal: International Journal of Molecular Sciences

Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

doi: 10.3390/ijms18102173

Figure Lengend Snippet: Nrf2-inducers trigger axonal re-growth in the shFxn. ( A ) Bright field photographs of untreated shFxn, 5 µM (24 h) SFN and 30 µM (24 h) DMF treated cells. A re-organization of the neurites network is evident; ( B ) The number of neurites has been measured by ImageJ software and normalized for number of cells (*** p <0.001; bar = 100 μm).

Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

Techniques: Software

Expression of NRF2 and its down-stream genes in fibroblasts of patients with FA. Fibroblasts of three patients expressing a 35% residual amount of frataxin and 65% of NRF2 ( A ), with respect to healthy subjects, were treated with 10 µM SFN (24 h), and mRNA levels of NRF2-downstream-genes were determined ( B ). * p < 0.05 and ** p < 0.01, with respect to control fibroblasts; # p < 0.05 and ## p < 0.01, with respect to untreated FA fibroblasts.

Journal: International Journal of Molecular Sciences

Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

doi: 10.3390/ijms18102173

Figure Lengend Snippet: Expression of NRF2 and its down-stream genes in fibroblasts of patients with FA. Fibroblasts of three patients expressing a 35% residual amount of frataxin and 65% of NRF2 ( A ), with respect to healthy subjects, were treated with 10 µM SFN (24 h), and mRNA levels of NRF2-downstream-genes were determined ( B ). * p < 0.05 and ** p < 0.01, with respect to control fibroblasts; # p < 0.05 and ## p < 0.01, with respect to untreated FA fibroblasts.

Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

Techniques: Expressing, Control

Frataxin and NRF2 mRNA levels in blood of patients with FA. qRT-PCR performed on PBMCs isolated from blood of FA patients ( n = 4) evidenced 35% and 59% residual amounts of Fxn and NRF2 expression, respectively, compared with healthy subjects ( n = 5) (* p < 0.05,** p < 0.01, respect to healthy subjects).

Journal: International Journal of Molecular Sciences

Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

doi: 10.3390/ijms18102173

Figure Lengend Snippet: Frataxin and NRF2 mRNA levels in blood of patients with FA. qRT-PCR performed on PBMCs isolated from blood of FA patients ( n = 4) evidenced 35% and 59% residual amounts of Fxn and NRF2 expression, respectively, compared with healthy subjects ( n = 5) (* p < 0.05,** p < 0.01, respect to healthy subjects).

Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

Techniques: Quantitative RT-PCR, Isolation, Expressing

Primers used for qRT-PCR.

Journal: International Journal of Molecular Sciences

Article Title: Nrf2-Inducers Counteract Neurodegeneration in Frataxin-Silenced Motor Neurons: Disclosing New Therapeutic Targets for Friedreich’s Ataxia

doi: 10.3390/ijms18102173

Figure Lengend Snippet: Primers used for qRT-PCR.

Article Snippet: Nrf2 inducers have been found to be neuroprotective in the MPTP model of PD [ , , ], in fragile X syndrome [ ], in multiple sclerosis [ , ], and a clinical trial with a novel Nrf2 activator (RTA 408) has been started for the treatment of FA (REATA Pharmaceuticals, ClinicalTrials.gov, NCT02255435).

Techniques: Sequencing